LLY

1,031.85

-1.94%↓

JNJ

244.39

-0.83%↓

ABBV

228.56

+0.18%↑

NVS

167.5

+0.02%↑

MRK

122.86

-0.94%↓

LLY

1,031.85

-1.94%↓

JNJ

244.39

-0.83%↓

ABBV

228.56

+0.18%↑

NVS

167.5

+0.02%↑

MRK

122.86

-0.94%↓

LLY

1,031.85

-1.94%↓

JNJ

244.39

-0.83%↓

ABBV

228.56

+0.18%↑

NVS

167.5

+0.02%↑

MRK

122.86

-0.94%↓

LLY

1,031.85

-1.94%↓

JNJ

244.39

-0.83%↓

ABBV

228.56

+0.18%↑

NVS

167.5

+0.02%↑

MRK

122.86

-0.94%↓

LLY

1,031.85

-1.94%↓

JNJ

244.39

-0.83%↓

ABBV

228.56

+0.18%↑

NVS

167.5

+0.02%↑

MRK

122.86

-0.94%↓

Search

CorMedix Inc

Abrir

SetorSaúde

7.27 3.12

Visão Geral

Variação de preço das ações

24h

Atual

Mín

7

Máximo

7.27

Indicadores-chave

By Trading Economics

Rendimento

89M

109M

Vendas

65M

104M

P/E

Médio do Setor

3.172

108.767

Margem de lucro

104.112

Funcionários

64

EBITDA

37M

57M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+95.01% upside

Dividendos

By Dow Jones

Próximos Ganhos

24 de mar. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-316M

552M

Abertura anterior

4.15

Fecho anterior

7.27

Sentimento de Notícias

By Acuity

54%

46%

288 / 351 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Strong Bullish Evidence

CorMedix Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

24 de fev. de 2026, 23:07 UTC

Ganhos

Woolworths 1st Half Profit Hit By Worker Pay Dispute, Still Boosts Dividend

24 de fev. de 2026, 23:01 UTC

Ganhos

Fortescue 1st Half Net Profit, Dividend Rise on Higher Shipments, Prices -- Update

24 de fev. de 2026, 22:59 UTC

Ganhos

WiseTech to Cut 2,000 Jobs as It Asks AI to Boost Profitability -- Update

24 de fev. de 2026, 22:42 UTC

Ganhos

WiseTech to Cut 2,000 Jobs as It Asks AI to Boost Profitability

24 de fev. de 2026, 22:24 UTC

Aquisições, Fusões, Aquisições de Empresas

Warner Bros. Discovery Board Says Paramount Skydance's New Proposal Could Top Netflix Agreement -- Update

24 de fev. de 2026, 23:46 UTC

Conversa de Mercado

Gold Edges Higher Amid Possible Position Adjustments -- Market Talk

24 de fev. de 2026, 23:36 UTC

Conversa de Mercado

Nikkei May Rise, Tracking Wall Street's Rebound -- Market Talk

24 de fev. de 2026, 23:30 UTC

Conversa de Mercado

Fortescue's Copper Bet Is Long Term, While Iron Ore Remains Near-Term Driver -- Market Talk

24 de fev. de 2026, 23:20 UTC

Conversa de Mercado

Fortescue Dividend Beat Overshadows Profit Miss -- Market Talk

24 de fev. de 2026, 23:20 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

24 de fev. de 2026, 23:16 UTC

Ganhos

Oversea-Chinese Banking Corp.'s CEO: "Looking Ahead, We Remain Cautious Yet Positive">O39.SG

24 de fev. de 2026, 23:13 UTC

Ganhos

Oversea-Chinese Banking Corp. FY25 Non-Interest Income S$5.46B Vs. S$4.72B >O39.SG

24 de fev. de 2026, 23:12 UTC

Ganhos

Oversea-Chinese Banking Corp.: FY25 Net Interest Income S$9.15B Vs. S$9.76B>O39.SG

24 de fev. de 2026, 23:10 UTC

Ganhos

Oversea-Chinese Banking Corp. FY25 NPL Ratio 0.9%, Unchanged on Year>O39.SG

24 de fev. de 2026, 23:10 UTC

Ganhos

Oversea-Chinese Banking Corp. FY25 Net Interest Margin 1.91%, Down 29bps on Year>O39.SG

24 de fev. de 2026, 23:08 UTC

Ganhos

Oversea-Chinese Banking Corp. FY25 Net S$7.42B Vs. Net S$7.59B >O39.SG

24 de fev. de 2026, 23:07 UTC

Ganhos

Oversea-Chinese Banking Corp. FY25 Total Income S$14.61B Vs. S$14.47B>O39.SG

24 de fev. de 2026, 22:52 UTC

Ganhos

Woolworths 1H Profit Hit By Worker Pay Dispute, Still Boosts Dividend

24 de fev. de 2026, 22:46 UTC

Ganhos

Fortescue 1H Net Profit, Dividend Rise on Higher Shipments, Prices -- Update

24 de fev. de 2026, 22:31 UTC

Aquisições, Fusões, Aquisições de Empresas

Warner Receives New Bid From Paramount -- 3rd Update

24 de fev. de 2026, 22:29 UTC

Ganhos

Woolworths: FY Ebit Growth for Australian Food Expected at Upper End of Mid-to-High Single Digit Range Provided in August

24 de fev. de 2026, 22:28 UTC

Ganhos

Woolworths: Australian Food Current Growth Rates Reflect Some Benefit from Cycling of Industrial Action Impacts

24 de fev. de 2026, 22:27 UTC

Ganhos

Woolworths: Australian Food Sales +7.2% Excluding Tobacco in 2H First Seven Weeks

24 de fev. de 2026, 22:27 UTC

Ganhos

Woolworths: Australian Food Sales +5.8% in 2H First Seven Weeks

24 de fev. de 2026, 22:25 UTC

Ganhos

Woolworths: Customers Continue to be Value-Focused, Shopping Multiple Retailers in Highly Competitive Environment

24 de fev. de 2026, 22:24 UTC

Ganhos

Woolworths: Trading in 3Q to Date Has Been Strong in Australian Food

24 de fev. de 2026, 22:23 UTC

Ganhos

Woolworths 1H Group Sales A$37.1 Bln, Up 3.4%

24 de fev. de 2026, 22:22 UTC

Ganhos

Woolworths Interim Dividend 45 Australian Cents/Share

24 de fev. de 2026, 22:22 UTC

Ganhos

Woolworths 1H Profit Before Significant Items A$859 Mln, Up 16.4%

24 de fev. de 2026, 22:21 UTC

Ganhos

Woolworths 1H Statutory Net Profit A$374 Mln, Down 49.4%

Comparação entre Pares

Variação de preço

CorMedix Inc Previsão

Preço-alvo

By TipRanks

95.01% parte superior

Previsão para 12 meses

Média 13.67 USD  95.01%

Máximo 15 USD

Mínimo 13 USD

Com base em 4 analistas de Wall Street que oferecem metas de preço de 12 meses para CorMedix Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

4 ratings

4

Comprar

0

Manter

0

Vender

Pontuação Técnica

By Trading Central

9.2 / N/ASuporte e Resistência

Curto Prazo

Strong Bullish Evidence

Médio Prazo

Weak Bullish Evidence

Longo Prazo

Strong Bullish Evidence

Sentimento

By Acuity

288 / 351 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Baixa

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre CorMedix Inc

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
help-icon Live chat